Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: dollarone who wrote (2296)	12/10/1998 7:34:00 PM
From: Jeffrey L. Henken	Respond to of 2887

I apologize. I did not realize you were actually a shareholder. As far as the technology goes and your assessment of the effect of passing time. I both agree and disagree. Every current(long) shareholder wishes ABMI had made more progress to date. That being said several facts still remain as far as I am concerned. 1.) No other company has as complete a 100% silicone catheter line. 2.) There are no FDA approved bifurcated stents on the market anywhere. ABMI has several patents. 3.) The OmniCath is approved for phase II trials and by all indications should be on the fast track because of it's many advantages over competitive devices. Atherectomy devices are seeing much more use than many would have thought with the advent of stenting. In fact the market is actually growing very nicely. 4.) As far as I know no other company is even conducting research into an arterial side temporary microfilter due to the broad patent protection that American BioMed has on the Omnifilter. If you have owned ABMI shares since 1996 then I can certainly understand why you are a disgruntled shareholder. The one thing I cannot understand is why you have given me so much personal grief. Regards, Jeff